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Abstract
Introduction: Currently, omalizumab is indicated for the treatment of patients with severe allergic uncontrolled
asthma despite optimal therapy.
Case presentation: We studied a 52-year-old man who has been suffering from severe non allergic steroid-
resistant asthma with increased levels of total IgE and a lot of comorbidity. After a 3 years long treatment with
omalizumab, he presented a significant improvement in disease control in terms of hospitalizations, exacerbation,
quality of life and lung function with good safety profile.
Conclusion: Our case shows, after a long follow-up, how omalizumab can be effective in a severe form of non-
atopic asthma. It is therefore hoped that further studies can identify indicators that are able to give to clinicians
information about patients who can be responsive to monoclonal anti-IgE antibody even if non allergic.
Introduction
Patients with severe asthma often have a poor control of
their disease; they represent the subgroup that absorbs
most of the costs [1,2]; for these reasons it has given
rise to the need to get new drugs able to improve con-
trol. The only biological drug available for the treatment
of severe asthma is omalizumab. A number of clinical
trials have been performed in order to evaluate either
the efficacy or the safety of the above-mentioned drug:
the results showed that this molecule is able to signifi-
cantly improve asthma control and quality of life, with
an excellent safety profile [3-5].
Actually, as set by the European Medicine Agency
(EMA) [6] and GINA Guidelines [7], in Europe omalizu-
mab is indicated as an add-on therapy aimed at improv-
ing asthma control in adult and adolescent patients (12
years of age and above) with severe persistent allergic
asthma who have a positive skin test or in vitro reactiv-
ity to a perennial aeroallergen and who show reduced
lung function (FEV1 <80%) as well as frequent daytime
symptoms or night-time awakenings and who have had
multiple documented severe asthma exacerbations
despite daily high-dose inhaled corticosteroids, plus a
long-acting inhaled beta2-agonist. This treatment option
is limited to patients with baseline IgE level of 30 to
1.500 IU/ml and body weight of 20 to 150 kg.
In this study we describe the case of a man suffering
from severe non-allergic steroid-resistant asthma asso-
ciated with important comorbidity in which omalizumab
induced an extraordinary improvement of symptoms,
health-related quality of life (HRQoL), exacerbations
and lung function.
Case Report
In May 2006 a Caucasian 52-year-old man came to our
observation because of severe persistent asthma not
controlled despite an extensive therapy (formoterol 18
mcg/day; budesonide 640 mcg/day; tiotropium bromide
18 mcg/day), oral steroids (prednisone 25 mg/day). The
patient has a history of 2 severe exacerbations with
hospitalization, several mild and moderate exacerbations
(4-5/year) treated with increase of systemic steroids, fre-
quent nocturnal awakenings (2-3 per night) and daily
use of salbutamol as rescue medication (3-4 times/day)
[7], frequent nocturnal awakenings (2-3 per night) and
daily use of albuterol as rescue medication (3-4 times/
day) with side effects related to inhaled steroid (oral
candidiasis) and LABA (tachycardia) that had prevented
him from increasing the dosage of these drugs.
He was a former smoker (9 pack-year), asthma and
rhinitis were diagnosed in 1991 and he was also affected
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moderate obesity, dyslipidemia and lactose intolerance.
He was hospitalized in the Respiratory Department
because of asthma exacerbation in 2004 and 2005. The
patient was not sensitized to aero- and food allergens
and his respiratory symptoms were not affected by sea-
sons. Vesicular breath sounds were markedly reduced
and wheezes were present. Lung function tests showed a
severe obstruction: FEV1 1.52 (46% of predicted) and
FEV1/FVC 0.41 [Table 1]. The ventilatory defect showed
reversibility (23%) after albuterol administration. A high-
resolution chest CT showed no signs of parenchymal
lung disease. Blood tests showed peripheral eosinophilia
(8%) and total IgE were 272.6 KIU/L without specific
IgE to inhalant or food allergens testing with Immuno-
Cap (Phadia, Sweden).
Even the skin prick test for common aeroallergens
was negative. The allergens we performed (both for
cutaneous and serological tests) were: grasses, parietaria
officinalis, ragweed, mugwort, plantain, birch, cypress,
walnut, dust mites, molds (Aspergillus Fumigatus,
Alternaria, Cladosporium, Penicillium), cat and dog
epithelium.
We used the Asthma Quality of Life Questionnaire
(AQLQ) [8] to assess the patient’s QoL with an initial
score of 1,71 points, indicating a poor HRQoL [Table
1]. Given the poor asthma control, the severe obstruc-
tion and total IgE, we hypothesized that treatment with
omalizumab could be effective, despite the absence of
sensitization to inhalant allergens.
The patient signed the informed consent and started
the treatment in July 2006 (300 mg every 15 days subcu-
taneously). An improvement in symptoms of asthma
control was evident after only 16 weeks of treatment;
the patient had no exacerbation. The lung function
parameters were essentially unchanged but the AQLQ
score increased to 3.23 [Table 1].
In order to evaluate the efficacy of omalizumab, the
Global Evaluation of Treatment Effectiveness scales
(GETE) [3,9,10] was used and the result was good. After
32 weeks of treatment the discontinuation of systemic
steroid and tiotropium was possible. In that interval,
there had been no exacerbations; spirometry showed a
slight worsening (FEV1 1.33 l), while the AQLQ score
was further improved (4.62). The GETE was excellent.
The patient was followed until July 2010 and in that
range he had only two mild relapses and no hospitaliza-
tion. The AQLQ score arrived at 5.43 confirming a
marked improvement in the quality of life; spirometry
showed a discrete increase (FEV1 1.70 l; 53% of pre-
dicted) compared to baseli n e( F E V 1+ 1 5 % ) .T h eG E T E
was confirmed excellent [Table 1].
Finally, the assay of serum IgE at the end of follow-up
was 419 IU/ml, with an increase compared to baseline.
Discussion
According to current guidelines, omalizumab is a safe
and effective add-on treatment which, in suitable
patients [7], allows them to obtain better control of
asthma by reducing the number of exacerbations and
the use of steroids and improving the quality of life
[3,4].
Actually, one only report [11] concerns the effective-
ness of this drug in a patient with non-allergic asthma
(who had high total IgE). Several authors showed that
the different phenotypes of asthma have several likeness,
with similar cytokine and cellular patterns both in aller-
gic and non-allergic asthma [12,13]. Therefore, IgE may
have a key role in the inflammatory cascade (even in
the absence of a proved aeroallergen) contributing to
bronchial hyper reactivity and remodeling in asthma.
Also, it is well known that higher values of IgE are asso-
ciated with higher hyper reactivity and more severe
obstruction [14].
Table 1 Omalizumab treatment effectiveness
Outcomes Basal Basal (post
beta agonist)
32-week 3-years 3-years (post
beta agonist)
GETE rating Excellent Excellent
AQLQ
(median, range)
1.71 3.23 5.43
FEV1 % 46% 60% 40% 53% 71%
FEV1/FVC 0.49 0.49 0.46 0.49 0.57
FEF25% 25% 30% 12% 26% 33%
FEF50% 15% 18% 13% 18% 22%
FEF75% 16% 14% 13% 13% 15%
Hospitalization 2 0 0
Exacerbation mild + moderate 5 for year 0 2 (-60%)
IgE 272.6 IU/ml 419 IU/ml
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not the only pharmacological effect of omalizumab, as it
also promotes the down-regulation of the expression of
the high-affinity receptor FcεRI, causing a further reduc-
tion of IgE on the cell surface [14,15].
Also, a study by Berger and cohautors showed that the
in vitro incubation with omalizumab of bronchial tissue
from asthmatic patients, inhibits specific and aspecific
bronchial hyper-responsiveness. This effect should be
related to the inhibition of bronchial mast-cells degranu-
lation [16].
Based on these considerations, we hypothesized that
treatment with omalizumab in our patient could be
effective, in spite of what is indicated by the guidelines
and the manufacturer.
The clinical and instrumental data show a significant
improvement in disease control in terms of hospitaliza-
tions and exacerbations. In order to evaluate the effec-
tiveness at 32 weeks and at 3 years, we used the Global
Evaluation of Treatment Effectiveness scale (GETE)
[3,9,10]. The evaluation is performed independently by
both investigator and patient using the same 5 point
scale. This scale ranges from excellent through good,
moderate, and poor to worsening. A good or excellent
response is suggested as a means of defining a patient
who has responded to treatment. In our patient the
GETE rating at 3 years was excellent, confirming the
effectiveness of omalizumab.
Health-related quality of life (HRQoL) was assessed
by means of the AQLQ score [8]. The AQLQ is com-
posed of 32 questions which cover four domains:
activity limitation, symptoms, environmental stimuli
and emotional function. Subjects recall their experi-
ences during the previous 2 weeks and score a number
of asthma-related problems on a 7-point scale from 1
(maximum impairment) to 7 (no impairment). We
used an overall summary index, which is the mean of
the responses to the 32 items (total AQLQ score). The
AQLQ was found to be valid, reproducible and
responsive to change over time and a change in
questionnaire score of 0.5 or more points has been
determined to be the minimal clinically important dif-
ference [8]. In our patient the quality of life improved
significantly, with the AQLQ score progressively
increasing over time. The lung function parameters
were stable during the first months, showing a rise
after four years. This could be explained by the bron-
chial remodelling caused by the long-standing ashtma,
which needed several months of therapy to appreciate
an improvement.
In our study, it is possible that specific allergic sensi-
tivity was simply not identified, as the range of potential
allergenic agents is considerably larger than current
diagnostic reagents can address, so false-negative aller-
gen-skin-test results are likely to happen.
Also, in this patient the contribution of placebo effects
cannot be excluded. However, improvements were seen
in objective parameters such as lung function and num-
ber of exacerbations as well as symptom improvement.
The possibility that the improvement is related to a
greater surveillance is unlikely as it was previously fol-
lowed consistently with good compliance. In addition,
the timing are closely related with the administration of
omalizumab.
A b o u tt h ei n c r e a s eo ft o t a lI g E ,i ti sw e l l - k n o w nt h a t
patients treated with omalizumab may exhibit reduction
of serum free IgE levels with increased total IgE due to
the formation of IgE anti-IgE small immune complexes,
which have a longer half-life than free IgE [17,18]. How-
ever, this increase has not pathological significance.
In conclusion, our work shows after a long follow-up
the effectiveness of omalizumab with a good safety profile
i nas e v e r ef o r mo fn o n - a t o p i ca s t h m aw i t hi n c r e a s e d
levels of total IgE. It is therefore hoped that further stu-
dies identify new indicators that can give to clinicians
information about asthmatic patients who can be respon-
sive to monoclonal anti-IgE antibody even if non allergic.
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